The potential of cord blood stem cells for use in regenerative medicine

David T. Harris, Michael Badowski, Nafees - Ahmad, Mohamed A. Gaballa

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

It is estimated that up to 128 million individuals might benefit from regenerative medicine therapy, or almost 1 in 3 individuals in the US. If accurate, the need to relieve suffering and reduce healthcare costs is an enormous motivator to rapidly bring stem cell therapies to the clinic. Unfortunately, embryonic stem (ES) cell therapies are limited at present by ethical and political constraints and, most importantly, by significant biologic hurdles. Thus, for the foreseeable future, the march of regenerative medicine to the clinic will depend on the development of non-ES cell therapies. At present, non-ES cells easily available in large numbers can be found in the bone marrow, adipose tissue and umbilical cord blood (CB). Each of these stem cells is being used to treat a variety of diseases. This review shows that CB contains multiple populations of pluripotent stem cells, and can be considered the best alternative to ES cells. CB stem cells are capable of giving rise to hematopoietic, epithelial, endothelial and neural tissues both in vitro and in vivo. Thus, CB stem cells are amenable to treat a wide variety of diseases including cardiovascular, ophthalmic, orthopedic, neurologic and endocrine diseases.

Original languageEnglish (US)
Pages (from-to)1311-1322
Number of pages12
JournalExpert Opinion on Biological Therapy
Volume7
Issue number9
DOIs
StatePublished - Sep 2007

Fingerprint

Regenerative Medicine
Stem cells
Fetal Blood
Blood Cells
Blood
Stem Cells
Cell- and Tissue-Based Therapy
Embryonic Stem Cells
Endocrine System Diseases
Pluripotent Stem Cells
Eye Diseases
Nervous System Diseases
Health Care Costs
Tissue
Endothelium
Embryonic Development
Orthopedics
Adipose Tissue
Cardiovascular Diseases
Bone Marrow

Keywords

  • Arthritis
  • Brain
  • Cartilage
  • Cornea
  • Diabetes
  • Heart
  • Liver
  • Regenerative medicine
  • Spinal cord injury
  • Stem cell
  • Stroke
  • Umbilical cord blood
  • Wound healing

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Genetics
  • Immunology

Cite this

The potential of cord blood stem cells for use in regenerative medicine. / Harris, David T.; Badowski, Michael; Ahmad, Nafees -; Gaballa, Mohamed A.

In: Expert Opinion on Biological Therapy, Vol. 7, No. 9, 09.2007, p. 1311-1322.

Research output: Contribution to journalArticle

@article{ead1234930ce45089b64dfff803ed085,
title = "The potential of cord blood stem cells for use in regenerative medicine",
abstract = "It is estimated that up to 128 million individuals might benefit from regenerative medicine therapy, or almost 1 in 3 individuals in the US. If accurate, the need to relieve suffering and reduce healthcare costs is an enormous motivator to rapidly bring stem cell therapies to the clinic. Unfortunately, embryonic stem (ES) cell therapies are limited at present by ethical and political constraints and, most importantly, by significant biologic hurdles. Thus, for the foreseeable future, the march of regenerative medicine to the clinic will depend on the development of non-ES cell therapies. At present, non-ES cells easily available in large numbers can be found in the bone marrow, adipose tissue and umbilical cord blood (CB). Each of these stem cells is being used to treat a variety of diseases. This review shows that CB contains multiple populations of pluripotent stem cells, and can be considered the best alternative to ES cells. CB stem cells are capable of giving rise to hematopoietic, epithelial, endothelial and neural tissues both in vitro and in vivo. Thus, CB stem cells are amenable to treat a wide variety of diseases including cardiovascular, ophthalmic, orthopedic, neurologic and endocrine diseases.",
keywords = "Arthritis, Brain, Cartilage, Cornea, Diabetes, Heart, Liver, Regenerative medicine, Spinal cord injury, Stem cell, Stroke, Umbilical cord blood, Wound healing",
author = "Harris, {David T.} and Michael Badowski and Ahmad, {Nafees -} and Gaballa, {Mohamed A.}",
year = "2007",
month = "9",
doi = "10.1517/14712598.7.9.1311",
language = "English (US)",
volume = "7",
pages = "1311--1322",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - The potential of cord blood stem cells for use in regenerative medicine

AU - Harris, David T.

AU - Badowski, Michael

AU - Ahmad, Nafees -

AU - Gaballa, Mohamed A.

PY - 2007/9

Y1 - 2007/9

N2 - It is estimated that up to 128 million individuals might benefit from regenerative medicine therapy, or almost 1 in 3 individuals in the US. If accurate, the need to relieve suffering and reduce healthcare costs is an enormous motivator to rapidly bring stem cell therapies to the clinic. Unfortunately, embryonic stem (ES) cell therapies are limited at present by ethical and political constraints and, most importantly, by significant biologic hurdles. Thus, for the foreseeable future, the march of regenerative medicine to the clinic will depend on the development of non-ES cell therapies. At present, non-ES cells easily available in large numbers can be found in the bone marrow, adipose tissue and umbilical cord blood (CB). Each of these stem cells is being used to treat a variety of diseases. This review shows that CB contains multiple populations of pluripotent stem cells, and can be considered the best alternative to ES cells. CB stem cells are capable of giving rise to hematopoietic, epithelial, endothelial and neural tissues both in vitro and in vivo. Thus, CB stem cells are amenable to treat a wide variety of diseases including cardiovascular, ophthalmic, orthopedic, neurologic and endocrine diseases.

AB - It is estimated that up to 128 million individuals might benefit from regenerative medicine therapy, or almost 1 in 3 individuals in the US. If accurate, the need to relieve suffering and reduce healthcare costs is an enormous motivator to rapidly bring stem cell therapies to the clinic. Unfortunately, embryonic stem (ES) cell therapies are limited at present by ethical and political constraints and, most importantly, by significant biologic hurdles. Thus, for the foreseeable future, the march of regenerative medicine to the clinic will depend on the development of non-ES cell therapies. At present, non-ES cells easily available in large numbers can be found in the bone marrow, adipose tissue and umbilical cord blood (CB). Each of these stem cells is being used to treat a variety of diseases. This review shows that CB contains multiple populations of pluripotent stem cells, and can be considered the best alternative to ES cells. CB stem cells are capable of giving rise to hematopoietic, epithelial, endothelial and neural tissues both in vitro and in vivo. Thus, CB stem cells are amenable to treat a wide variety of diseases including cardiovascular, ophthalmic, orthopedic, neurologic and endocrine diseases.

KW - Arthritis

KW - Brain

KW - Cartilage

KW - Cornea

KW - Diabetes

KW - Heart

KW - Liver

KW - Regenerative medicine

KW - Spinal cord injury

KW - Stem cell

KW - Stroke

KW - Umbilical cord blood

KW - Wound healing

UR - http://www.scopus.com/inward/record.url?scp=34748833133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34748833133&partnerID=8YFLogxK

U2 - 10.1517/14712598.7.9.1311

DO - 10.1517/14712598.7.9.1311

M3 - Article

C2 - 17727322

AN - SCOPUS:34748833133

VL - 7

SP - 1311

EP - 1322

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 9

ER -